Roche to Highlight the P-III (OCARINA II) Trial Results of Ocrevus for Treating Progressive and Relapsing Multiple Sclerosis at AAN 2024
Shots:
- The P-III (OCARINA II) trial assesses the safety, PK profile as well as radiological & clinical effects of Ocrevus (920mg, SC) vs Ocrevus (IV) to treat patients (n=236) with relapsing MS (RMS) or primary progressive MS (PPMS)
- The updated, long-term data demonstrated a near-complete relapse activity suppression (97% had no relapse) & reduced MRI at 48wks. as well as an ARR of 0.04 with patients showing no T1 Gd+ & new/enlarging T2 lesions. Exploratory patient reported outcomes (n=52) suggested high satisfaction (92.3%) & convenience (90.1%) with Ocrevus SC injection
- Moreover, the company’s submissions have been accepted by the EMA & the US FDA with the decision anticipated in mid-2024 and Sep 2024, respectively
Ref: Roche | Image: Roche
Related News:- Genentech Reports P-III Study (OCARINA II) Results of Ocrevus for the Treatment of Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
